Noisy ← this week

The world is being quietly rearranged by people who write very long documents.

March 30, 2026
Federal Register
The title they went with
Microbiology Devices; Reclassification of Mycobacterium Tuberculosis Cell-Mediated Immunity Tests and Immune Response Enzyme-Linked Immunospot Tests Noisy translates that to

FDA finally loosens approval rules for TB tests, fifteen years after first trying

The regulatory category requiring the most stringent evidence before market entry is, in this case, the thing that slowed access to better diagnostics for a disease with abundant evidence and over a million deaths a year. The caution was the problem.
What happened
US health regulators are proposing to move certain tuberculosis infection tests from a high-risk category requiring extensive review to a lower-risk category. This means these tests will need less rigorous approval processes, making them easier and faster to bring to market.
before Both test types were class III devices requiring full premarket approval (PMA) before entering the market.
after If finalized, both test types would be reclassified to class II, requiring only premarket notification (510(k)) plus compliance with new special controls.
Why this matters
For decades, new diagnostic tests for tuberculosis have faced a slow and expensive approval process. This change allows for new types of tests to be evaluated using updated standards. It could speed up the availability of better diagnostic tools, especially for infections that are hard to detect.
A unanimous expert panel in 2023 said the data was sufficient. The proposal to act on that finding arrived in 2026. Institutions move at the speed they choose to move at.
Who wins, who loses
who wins Diagnostic device manufacturers who will face a less burdensome premarket notification pathway instead of full premarket approval; clinicians and patients who may gain faster access to new TB diagnostic tools.
also TB diagnostic manufacturers who filed a citizen petition in 2019 and waited seven years for a proposed rule, and the public health programs in high-burden countries that have been making do with older tools in the meantime.
The signal
Why this hasn't landed yet
It reads as a technical reclassification inside a regulatory subcategory most people have never heard of — product codes NCD and OJN do not make headlines. The downstream effect on diagnostic access is real but diffuse and slow, which makes it invisible to any news cycle shorter than a decade.
What happens next
Manufacturers who parked TB diagnostic development because the full premarket approval cost made the market math not work can now revisit those decisions. Expect development programs to restart and new 510(k) submissions to follow, probably within two to three years of finalization.
The catch
Reclassification to Class II with special controls only helps if the special controls are workable — and FDA has not yet published what those controls will require. The 2011 panel stalled partly because members could not agree on what adequate controls looked like. If the new special controls are drafted too broadly, the practical burden may not shrink as much as the category change implies.
The longer story
The longer arc
The FDA first seriously discussed moving these TB tests out of Class III in 2011, declined, and spent the next decade watching HIV viral load tests, hepatitis C assays, and nucleic acid-based TB detection tests all make the same journey successfully. This proposal is the last significant TB diagnostic category to follow that path.
Part of a pattern
Part of an explicit FDA-wide initiative. In January 2024, CDRH announced plans to reclassify most Class III in-vitro diagnostics. Hepatitis B antigen and antibody tests followed in September 2025. HIV viral load tests moved in November 2022. These TB tests are the current item on a running list.
If you insist
Read the original →
The Sendoff
The advisory panel voted unanimously in 2023 that reclassification was appropriate. The proposed rule arrived in March 2026. The comment period is now open.